All HHS Contracts — June 25, 2026
The single HHS contract analyzed for June 25, 2026, a $63.1M cost-plus-fixed-fee delivery order awarded to Leidos Biomedical Research Inc. by NIH/NCI for R&D facility operations, is purely civilian, defense-unrelated, and carries a neutral signal (strength 5/10). Revenue is steady but non-transformative for Leidos Holdings, representing approximately 0.1% of annual revenue, with low pricing risk but limited upside given the cost-plus structure and short one-year performance period. The highest-conviction signal is stability in NIH cancer research funding, though the absence of option exercise or follow-on awards introduces revenue discontinuity risk. Key watch item is re-competition timing at NIH NCI for similar GOCO facility operations contracts.